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Abstract 1 
Langerhans cell histiocytosis (LCH) is a rare disease characterized by clonal proliferation of CD1a- and 2 
CD207 (langerin)-positive dendritic cells. Mutated BRAF (p.V600E) is observed in histiocyte-related diseases 3 
and dendritic cell-related diseases, including LCH. BRAFV600E is observed in some LCH cases and is thought 4 
to be involved in maintaining MAPK activation. We retrospectively analyzed BRAFV600E in 19 patients 5 
diagnosed with LCH. In our study, direct sequencing for exon 15, a mutation hotspot, demonstrated that 4 out 6 
of the 19 patients (21%) harbored a GTG>GAG (valine>glutamic acid) base substitution, which encodes 7 
BRAFV600E. The clinical impact of BRAFV600E in such diseases is unclear. The frequency of BRAFV600E 8 
in our LCH patients from Japan was lower than that reported in the United States and in Germany. However, 9 
reports from Asia tend to show a lower rate of the BRAFV600E mutation. These results imply the possibility 10 
of different genetic backgrounds in the pathogenesis of LCH across various ethnicities. We also performed an 11 
immunohistochemical analysis to detect BRAFV600E using the mutation-specific monoclonal antibody. 12 
However, immunohistochemical analysis failed to detect any mutated protein in any of the 4 BRAFV600E-13 
positive cases. This implies that at present, BRAFV600E should be assessed by direct sequencing. 14 
 15 
  16 
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Introduction 1 
Langerhans cell histiocytosis (LCH) is a disease characterized by clonal proliferation of CD1a- and CD207 2 
(langerin)-positive dendritic cells [1, 2]. It is a very rare disease, with a prevalence of 5 to 10 in 1,000,000 3 
people. The male-to-female ratio is 2:1 [3]. LCH affects a wide range of age groups, from newborns to the 4 
elderly. The manner of involvement varies, and single-organ local involvement (single-system single-site; SS), 5 
single-organ multiple involvement (single-system multi-site; SM), and multi-organ multiple involvement 6 
(multi-system multi-site; MM) are recognized. In SS-type LCH, lesion(s) may disappear upon follow-up 7 
without treatment, but SM- and MM-type LCH are often treated with chemotherapy [4, 5].  8 
 9 
BRAF is a protein belonging to the serine/threonine kinases, and it plays an important role in the 10 
mitogen-activated protein kinase (MAPK) pathway. MAPK regulates cell maintenance and proliferation in 11 
some solid tumors, such as melanoma and colon cancer. The genetic mutation BRAFV600E is observed in 12 
histiocyte-related diseases and dendritic cell-related diseases, including LCH [6]. The BRAFV600E mutation 13 
is also observed in some LCH cases and is thought to be involved in maintaining MAPK activation [7]. 14 
 15 
Using mass spectrometry analysis, Badalian-Very et al. showed BRAFV600E to be present in 35 of 61 cases 16 
of LCH (57%) in the United States [8]. Reported frequencies of BRAFV600E in LCH patients in other 17 
countries are 34 of 89 (38%) in Germany [9], 7 of 15 (47%) in Hungary [10], and 6 of 27 (22%) in South 18 
Korea [6]. In contrast with these figures, Tong et al. found no BRAFV600E in any of the 18 LCH patients they 19 
studied in China recently [11]. This implies that different ethnicities have different rates of BRAF mutations 20 
5 
 
in LCH. We retrospectively analyzed BRAFV600E among Japanese people affected with LCH by using direct 1 
sequencing and immunohistochemistry (IHC). Here, we present the results of these assays, along with clinical 2 
information. 3 
 4 
  5 
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Materials and methods 1 
Patients and data collection 2 
This retrospective analysis was conducted in 19 patients diagnosed with LCH, whose samples were submitted 3 
for diagnosis to the Department of Pathology, Kurume University, Kurume, Japan (Table 1). Among the 19 4 
cases, we obtained prognostic information in 14 cases. Patients with histiocytic sarcoma and Erdheim–5 
Chester disease (ECD) were excluded from this study.  6 
 7 
Paraffin-embedded tissues were available from all 19 LCH patients. All biopsied samples were 8 
obtained prior to any therapy. The study received approval from the Research Ethics Committee of Kurume 9 
University and was performed according to the principles of the Helsinki Declaration. The reporting system 10 
for materials and clinical information ensured the anonymity of patients. 11 
 12 
Morphologic analysis 13 
The diagnosis of LCH was based on clinical and histologic diagnosis. Biopsies were performed in all LCH 14 
patients. Histopathological evaluation of initial samples was done using formalin-fixed, paraffin-embedded 15 
(FFPE) blocks.  16 
 17 
Immunohistochemistry 18 
The original diagnosis was also supported by IHC using CD1a (mouse monoclonal antibody, clone MTB1; 19 
Leica Biosystems, Newcastle upon Tyne, UK), CD207 / langerin (mouse monoclonal antibody, clone 12D6; 20 
7 
 
Leica Biosystems), and S100 (polyclonal rabbit antibody, Dako, Glostrup, Denmark). To evaluate the presence 1 
of BRAF protein in LCH, we also performed IHC using a mouse monoclonal BRAFV600E antibody (mouse 2 
monoclonal antibody, clone VE1; Spring Bioscience, Pleasanton, CA, USA). The antibody was constructed 3 
for detection of the mutant protein BRAFV600E. In particular, the BRAFV600E antibody (dilution: 1:100) 4 
was used in IHC with the EnVision G|2 Doublestain System (Dako, Glostrup, Denmark) for detection of the 5 
mutant protein BRAFV600E in sections of 2.5-µm thickness cut from FFPE blocks after heat-induced antigen 6 
retrieval (boiling for 40 minutes at 95°C, in 10 mM Tris-buffer/1 mM EDTA, pH 9.0).  7 
 8 
  9 
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DNA isolation and BRAFV600E mutation analysis in direct sequencing 1 
We performed BRAF mutation analysis in 19 LCH patients by direct sequencing. Tumor DNA was isolated 2 
from the relevant FFPE tissue blocks by cutting 10-µm-thick sections followed by extraction using KAPA 3 
Express Extract Kits (Kapa Biosystems). The median estimate of the tumor percentage in the biopsied sample 4 
was 50% (10-90%). BRAF exon 15, a mutation hotspot, was amplified by semi-nested polymerase chain 5 
reaction (PCR). In the first round, PCR was performed using KAPA2G Robust PCR Kits (forward primer, 5ʹ-6 
TAAACTCTTCATAATGCTTGCTTGCTCTGAT-3ʹ; reverse primer, 5ʹ-7 
AACTCAGCAGCATCTCAGGGCCAA-3ʹ) on a GeneAtlas 482 thermal cycler (ASTEC) with the following 8 
cycling conditions: initial denaturation at 95°C for 10 min; 40 cycles of denaturation at 95°C for 30 s, 9 
annealing at 60°C for 20 s, and extension at 72°C for 30 s; and final extension at 72°C for 10 min. In the 10 
second step, PCR was performed using AmpliTaq Gold DNA Polymerase (Applied Biosystems) (forward 11 
primer, 5ʹ-CATAATGCTTGCTCTGATAGGAAAATGAG-3ʹ; reverse primer, 5ʹ-12 
AACTCAGCAGCATCTCAGGGCCAA-3ʹ) on the GeneAtlas 482 thermal cycler with the following cycling 13 
conditions: initial denaturation at 95°C for 10 min; 40 cycles of denaturation at 95°C for 30 s, annealing at 14 
60°C for 20 s, and extension at 72°C for 30 s; and final extension at 72°C for 10 min. The positive control 15 
was β-actin in each set of amplifications. PCR products were detected by 2% agarose gel electrophoresis and 16 
then purified and sequenced on an ABI PRISM 310 Genetic Analyzer (Life Technologies). Analyses of the 17 
sequence data were performed by using GENETYX software Ver.10 (GENETYX). The reference sequence 18 
was a DNA sequence complementary to the BRAF sequence.  19 
 20 
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 1 
Results 2 
Morphologic analysis and Immunohistochemistry 3 
Hematoxylin-eosin (HE) staining of the biopsies showed features of LCH (e.g., abnormal histiocytic cells, 4 
eosinophils, small lymphocytes, and macrophages). CD1a, CD207/langerin and S100 were all positive in all 5 
cases (Figure 1). 6 
 7 
BRAFV600E mutation 8 
BRAFV600E mutation analysis was performed in 19 patients. Direct sequencing for exon 15 demonstrated 4 9 
patients to have a GTG>GAG (valine>glutamic acid) base substitution, which leads to the production of 10 
mutant protein BRAFV600E (Figure 2). However no mutated protein was found in patients found to be 11 
BRAFV600E-positive by direct sequencing (Figure 1). IHC failed to detect mutated protein in any of the cases, 12 
indicating a discrepancy between the direct sequencing results and the IHC results (Table 1).  13 
 14 
Clinical course and treatment 15 
Of the 19 patients, 9 were male and 10 were female. The manner of involvement was SS in 9 cases, SM in 1 16 
case, and MM in 9 cases. Table 2 summarizes the sites of involvement at diagnosis. Patient 17 had a 17 
complication of central diabetes insipidus. The median observation period was 39 months; 11 patients survived, 18 
and 3 died due to either the underlying disease or related complications.  19 
 20 
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SS-type LCH patients, except patients 4 and 5, underwent follow-up without treatment, while most 1 
SM and MM-type LCH patients received chemotherapy (Table 3). Chemotherapy was performed for patient 2 
3 because he experienced disease progression during watchful waiting. Patient 4 received chemotherapy 3 
because he experienced gait disturbance and pain due to nerve involvement of the tumor. In 9 patients, the 4 
regimen of the JLSG-02 protocol (Ara-C, vincristine, and prednisolone), designed by the Japan LCH Study 5 
Group, was used [12]. Patient 11 showed refractory disease and received allogeneic umbilical cord blood 6 
transplantation. However, she died due to transplant-related events. In patients 16 and 17, initial treatment was 7 
insufficiently effective. They therefore received salvage therapy with cladribine, and remission of the tumor 8 
cells was achieved in both patients. 9 
 10 
 11 
  12 
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Discussion 1 
Currently, there is agreement that LCH is a clonal neoplasm. In the present report, the fact that the BRAFV600E 2 
mutation was present in some LCH patients supports the neoplastic nature of LCH. Berres et al. found the 3 
BRAFV600E mutation in 64% of LCH patients in the United States. Interestingly, the same group found that 4 
the presence of BRAFV600E in LCH patients was not related to the prognosis [13]. Go et al. reported the 5 
BRAFV600E mutation to also be present in histiocytic diseases other than LCH [6]. More specifically, they 6 
observed the BRAFV600E mutation in 1 of 1 (100%) case of Langerhans cell sarcoma, 5 of 8 (62.5%) cases 7 
of histiocytic sarcoma, 1 of 10 (10%) cases of giant cell tumor of the bone, and 1 of 20 (5%) cases of 8 
tenosynovial giant cell tumor. 9 
 10 
In our study, BRAFV600E was noted in 4 out of 19 Japanese patients (21%). This proportion is lower 11 
than that reported by Badalian-Very et al. in the United States (57%), Sahm et al. in Germany (38%), and 12 
Méhes, et al. in Hungary (47%) [8-10]. In contrast, reports from Asia have demonstrated a lower frequency of 13 
this mutation. Go et al. showed BRAFV600E in 22.2% of LCH cases in South Korea, while Tong et al. did not 14 
detect it in any of the 18 cases they analyzed in China [6, 11]. These results imply that the genetic basis 15 
underlying the pathogenesis of LCH differs by ethnicity.  16 
 17 
Additionally, Badlian-Very et al. previously demonstrated that MEK and ERK, which are downstream 18 
effectors of the MAPK pathway, are phosphorylated in LCH irrespective of the existence of the BRAFV600E 19 
mutation [8]. The fact that MEK and ERK were phosphorylated in LCH irrespective of the BRAFV600E 20 
12 
 
mutation might explain the finding by Marie et al. that LCH patients with BRAFV600E and LCH patients with 1 
wild-type BRAF had similar prognoses. It remains unknown why LCH patients lacking the BRAFV600E 2 
mutation have continuous activation of genes downstream of MAPK signaling [8]. A recent report by Noah et 3 
al. in the United States showed that 18 out of 40 (45%) LCH patients without the BRAFV600E mutation had 4 
MAP2K1 (also known as MEK1) mutations. The mutations were found in the exon 2 region or exon 3 region 5 
of MAP2K1 [14]. MAP2K1 is a gene found downstream of BRAF, and this finding suggests that the activation 6 
of the MAPK pathway does not require the BRAFV600E mutation in some LCH cases. It is therefore 7 
speculated that other elements, such as MAP2K1 mutations, are involved in the pathogenesis of LCH. Further 8 
studies are needed to clarify whether MAP2K1 mutations also occur in Japanese LCH cases and to determine 9 
the factors related to disease progression of LCH.  10 
 11 
In the present study, a BRAFV600E-specific monoclonal antibody was used to detect the mutant 12 
protein of BRAF by IHC. However, no mutated protein was found in any of the 4 BRAFV600E-positive 13 
patients. Such discordance regarding BRAF status between the result of direct sequencing and IHC often 14 
occurs [9, 10]. Løes et al. stated that Sanger sequencing yielded superior results to IHC using the same primary 15 
antibody that we used, VE1, in colon cancer [15]. This implies that at present, BRAFV600E should be assessed 16 
by direct sequencing. 17 
 18 
The efficacy of vemurafenib, a BRAFV600E inhibitor, has not been definitively assessed in LCH; 19 
however, some reports have described it to be effective in histiocytic diseases like hairy cell leukemia and 20 
13 
 
complicating ECD and LCH [16-18]. Further analyses are needed to evaluate therapeutic effects of 1 
vemurafenib against LCH with BRAFV600E. In BRAFV600E-negative cases, MEK inhibitors may be 2 
candidates for targeted therapy. It should be recognized that many LCH cases are pediatric, and it is therefore 3 
necessary to pay close attention to the long-term side effects of cytotoxic chemotherapy.  4 
 5 
In the path ahead, molecular-targeted therapies having less serious side-effects need to be developed. 6 
Investigating treatment strategies that also take growth and development into account remains an important 7 
task. In addition, further studies are warranted to clarify whether MAP2K1 mutations also occur in Japanese 8 
LCH patients and to identify the factors related to disease progression of LCH. Variation in the genetic basis 9 
of LCH pathogenesis among different ethnicities is another interesting feature worth exploring and might 10 
unravel novel therapeutic targets. 11 
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 1 
Seq IHC Skin Soft tissue Oral cavity Bone BM LN Liver Spleen Lung GI CNS
1 LCH 0 F SS Skin Wt N/E + - - - - - - - - - - -
2 LCH 0 F SS Lymph node Wt N/E N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
3 LCH 1 F SS Lymph node Wt N/E N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
4 LCH 1 M SS Soft tissue Wt N/E - + - - - - - - - - - -
5 LCH 2 M SS External ear canal Wt N/E + - - + - - - - - - - -
6 LCH 4 F SS Bone Wt N/E N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
7 LCH 5 M SS Bone V600E N/E - - - + - - - - - - - -
8 LCH 11 M SS Frontal sinus Wt N/E - - - + - - - - - - - -
9 LCH 13 F SS Thyroid gland Wt N/E N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
10 LCH 1 M SM Bone Wt N/E - - - + - - - - - - - -
11 LCH 0 F MM Spleen Wt N/E + - - - - - + + + - - -
12 LCH 0 M MM Lymph node Wt N/E - - - - - + + - - - - -
13 LCH 1 F MM Skin V600E N/E + - - + - + - - - - - -
14 LCH 1 M MM Bone V600E N/E + - - + - - - - - - - -
15 LCH 3 F MM Bone V600E N/E - + - - - + - - - - - -
16 LCH 3 M MM Skin Wt N/E + - - - + - - - - - - -
17 LCH 27 F MM Pituitary gland Wt N/E - - + + - - - - - - + +
18 LCH 57 M MM Skin Wt N/E + - - - N/A + - - - - - -
19 LCH 71 F MM Lymph node Wt N/E + + - - - + - - - - - -
      Seq, result of direct sequence; IHC, result of immunohistochemistry; LCH, Langerhans cell histiocytosis; M, male; F, female; SS, single-system single-site;
      SM, single-sistem multi-site; MM, multi-system multi-site;  N/E, Not estimable; BM, bone marrow; LN, lymph node; GI, stomach and intestine; CNS, central nervous system;
      DI, diabetes insipidus; N/A, not applicable
BRAF Status Extention Coexiste
nce
of DI
Table 1　 Patient profile and the results of BRAFV600E mutation analysis by direct sequencing and IHC and clinical features
Case Diagnosis
Age (y)
at diagnosis
Sex Extension Tested tissue
 2 
3 
19 
 
  1 
Case Initilal therapy
Effect of
initial therapy
Salvage therapy
Effect of
salvage therapy
Follow-up
(months)
Status
1 Watchful waiting  - - - 46 Alive
2 L/F L/F L/F L/F L/F L/F
3 L/F L/F L/F L/F L/F L/F
4 JLSG-02 RD - - 23 Alive
5 VCR+PSL PD JLSG-02 PD 56 Dead
6 L/F L/F L/F L/F L/F L/F
7 Watchful waiting  RD - - 7 Alive
8 Watchful waiting  - - - 39 Alive
9 L/F L/F L/F L/F L/F L/F
10 JLSG-02 RD - - 27 Alive
11 JLSG-02 PD HD Chemo+URCBT N/A 8 Dead
12 JLSG-02 RD - - 84 Alive
13 JLSG-02 RD L/F L/F 1 L/F
14 JLSG-02 RD - - 40 Alive
15 JLSG-02 RD - - 48 Alive
16 JLSG-02 PD CdA +Ara-C - 23 Dead
17 JLSG-02 PD CdA RD 40 Alive
18 IFRT RD - - 60 Alive
19 MTX SD - - 32 Alive
Table 2　Treatment and outcome
L/F, loss of follow-up; JLSG-02, Japan Langerhans Study Group Regimen 2002;  VCR, vincrisrtine;
PSL, prednisolone; IFRT, involved field radiation therapy; MTX, metotrexate;  N/A, not applicable;
RD, regressive disease; SD, stable disease; PD, progressive disease;
HD Chemo, high dose chemotherapy; URCBT, unrelated cord blood transplantation;
CdA, cladribine; Ara-C, cytarabine
20 
 
 1 
Figure legends 2 
 3 
Figure 1 Morphologic and immunohistochemical findings in patient 15. 4 
A The subcutaneous area is diffusely infiltrated by atypical cells (hematoxylin-eosin; original magnification, 5 
×100).  6 
B The neoplastic cells with pale cytoplasm are medium to large in size (hematoxylin-eosin; original  7 
magnification, ×400).  8 
C Atypical histiocytic cells are positive for CD1a (original magnification, ×400). 9 
D Atypical histiocytic cells are positive for CD207 (langerin) (original magnification, ×400). 10 
E Atypical histiocytic cells are positive for S100 (original magnification, ×400). 11 
F Atypical histiocytic cells are negative for BRAFV600E (original magnification, ×400). 12 
 13 
 14 
 15 
 16 
 17 
  18 
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Figure 2 Results of BRAF mutation analysis. 1 
Direct sequencing for exon 15 demonstrated 4 cases have GTG>GAG (valine>glutamic acid) base 2 
substitution, which encodes BRAFV600E. 3 
 4 
 5 
 6 
 7 
